Provided by Tiger Fintech (Singapore) Pte. Ltd.

Inhibrx Biosciences

11.98
-0.1800-1.48%
Post-market: 11.980.00000.00%16:02 EDT
Volume:45.79K
Turnover:549.99K
Market Cap:173.42M
PE:0.11
High:12.74
Open:12.19
Low:11.88
Close:12.16
Loading ...

Company Profile

Company Name:
Inhibrx Biosciences
Exchange:
NASDAQ
Establishment Date:
2024
Employees:
159
Office Location:
11025 North Torrey Pines Road,Suite 140,La Jolla,California,United States
Zip Code:
92037
Fax:
- -
Introduction:
Inhibrx, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has collaboration with 2seventy bio, Inc., Bristol-Myers Squibb Company, and Chiesi Farmaceutici S.p.A. The company was founded in 2010 and is headquartered in La Jolla, California.

Directors

Name
Position
Mark P. Lappe
Chief Executive Officer, President and Chairman of the board
Douglas G. Forsyth
Director
Jon Faiz Kayyem
Director
Kimberly Manhard
Director
Kristiina Vuori
Director

Shareholders

Name
Position
Mark P. Lappe
Chief Executive Officer, President and Chairman of the board
Kelly D. Deck
Chief Financial Officer
Brendan P. Eckelman
Chief Scientific Officer